Viewing records where tag name contains "home" View All

Starpharma presents promising additional clinical data for DEP® cabazitaxel in prostate cancer

Sep 12th, 2022

Starpharma announces additional results from the mCRPC cohort of its Phase 2 DEP® cabazitaxel trial, following completion of dosing in this cohort. Treatment with DEP® cabazitaxel showed a number of key advantages compared to published data for conventional cabazitaxel, including superior efficacy, as measured by longer PFS, and a lower incidence of key side effects, despite this patient cohort being relatively more heavily pre-treated.

Read More

Starpharma signs new DEP® agreement with MSD

Aug 10th, 2022

Starpharma today announced it has signed a new DEP® Research Agreement with MSD, the trade name of Merck Sharp & Dohme LLC, Rahway, NJ, USA. This new agreement follows an earlier DEP® Antibody Drug Conjugate (ADC) agreement signed with MSD in February 2021. Under the new agreement, Starpharma will design and synthesize a number of DEP® dendrimer conjugates and will provide them to MSD for testing and characterisation.

Read More

Starpharma to present DEP® at Boston ADC summit (ASX Announcement)

Apr 27th, 2022

Starpharma (ASX: SPL, OTCQX: SPHRY) today announced that it will today present as an invited speaker at the Novel Format Conjugates Summit, an industry conference focusing on next generation Non-Traditional Antibody Drug Conjugates (ADCs) for oncology and beyond.

Read More

Dr Jeff Davies appointed as non-executive director (ASX Announcement)

Apr 1st, 2022

Melbourne, Australia; 1 April 2022: Starpharma (ASX: SPL, OTCQX: SPHRY) today announced that Dr Jeff Davies has commenced as an independent non-executive director, effective 1 April 2022.   ... Dr Davies is a former CSL executive, with over 35 years of biopharmaceutical experience, holding senior executive roles at CSL, including Executive Vice President & General Manager at... Read More

Dr Jeff Davies appointed as non-executive director (ASX Announcement)

Feb 24th, 2022

Starpharma Holdings Limited The Board of Starpharma (ASX: SPL, OTCQX: SPHRY) is pleased to announce the appointment of Dr Jeff Davies as an independent non-executive director, effective 1 April 2022.  

Read More

Positive DEP® phase 2 interim results in prostate cancer (ASX Announcement)

Nov 25th, 2021

Starpharma today announced positive interim results from its ongoing phase 2 trial of DEP® cabazitaxel, showing that 100% (22/22) of evaluable patients with hormone refractory, (Stage IV) metastatic prostate cancer. All of these patients have been heavily pre-treated and have had efficacy responses, utilising one or more standard measures of disease.

Read More

AstraZeneca to present AZD0466 posters at ASH Meeting

Nov 5th, 2021

AstraZeneca will present two scientific posters each accompanied by a presentation at the 2021 American Society of Hematology (ASH) Annual Meeting, showcasing AstraZeneca’s first DEP® oncology product, AZD0466.

Read More

Starpharma to present DEP® at US Drug Delivery Conference (ASX Announcement)

Oct 28th, 2021

Starpharma today announced that it has been invited to present at the 11th annual Partnership Opportunities in Drug Delivery (PODD) conference, which will take place virtually this year on 28‑29 October 2021.

Read More

2021 Annual General Meeting (ASX Announcement)

Oct 1st, 2021

Starpharma today notifies that the AGM of Starpharma Holdings Limited will be held as a virtual event at 11:00am (Melbourne time) on Tuesday, 30 November 2021.

Read More

US patent issued for DEP® cabazitaxel nanoparticle (ASX Announcement)

Sep 15th, 2021

Starpharma today announced that the US Patent and Trademark Office has granted a new patent in relation to DEP® cabazitaxel.

Read More